In an enlightening conversation on Global Market Bulletin TV, Reunion Neuroscience’s CEO Greg Mayes, alongside host Leyla Gulen, delved into the recent strides the company has made in the mental health sector. A highlight of the discussion was the appointment of Dr. Robert Alexander as the Chief Medical Officer, marking a pivotal moment for the company. This strategic move aligns with the successful wrap-up of the Phase 1 clinical trial analysis of RE104, a promising 4-OH-DiPT prodrug that’s setting new benchmarks in the field of serotonergic psychedelics.
Greg Mayes, at the helm of Reunion Neuroscience since 2022, has been instrumental in steering the company towards groundbreaking discoveries in the treatment of mental health disorders, particularly postpartum depression. Under his leadership, RE104 emerged as a beacon of hope for many, showcasing potential for rapid symptom relief and sustained efficacy. The company is now gearing up to launch the Phase 2 study in postpartum depression, anticipated to commence in 2023.
The discussion also shed light on the RE200 series, a suite of compounds under preclinical research, designed for targeted serotonin receptor activity. This innovation underscores Reunion’s commitment to developing nuanced treatments that address specific aspects of mental health disorders.
Reunion Neuroscience stands at the forefront of addressing the pressing need for effective treatments in mental health, especially postpartum depression—a condition often overshadowed in the broader mental health discourse. With a patent extending until 2041 for their unique hemi-ester tryptamines, the company is well-positioned to lead the charge in this vital healthcare sector.
Mayes, with a rich background in propelling early-stage biotech and pharmaceutical companies to success, brings a wealth of experience to Reunion. His previous accomplishments include securing significant investment capital and spearheading the successful acquisition of Engage Therapeutics by UCB Pharma, following a fruitful Phase 2b clinical trial.
As Reunion Neuroscience continues its journey, the mental health community watches with keen interest, hopeful for the new possibilities that RE104 and the RE200 series may unlock in the battle against mental health disorders.
